drugset / Trial / NCT00548925

A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00548925

Phase 2 Completed 124 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of a 6 mg twice a day dose of an investigational product in subjects with diabetic neuropathy

Timeline

Start
2007-11
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SOFINICLINE Small molecule 6 mg